MetaCap

DBV Technologies S.A. ADR (DBVT)

NASDAQ: DBVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

9.02-0.40 (-4.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DBVT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$566.82M
EPS (TTM)
-$3.00
52-week range
8.63 – 26.19
Day range
9.00 – 9.47
Volume / Avg
156.50K / 352.88K
Beta
—

52-week range

$8.63$26.19

DBVT stock today

On Nov 20, DBVT ended the session at $9.02, shedding $0.40 (4.25%), versus the S&P 500's 3.70% decline. Trading was light, with 156.50K shares changing hands, about 44% of the average daily volume. At this level, DBVT sits near the bottom of its 52-week range of $8.63 to $26.19: 65.6% below the high, set on Dec 17, 2025 and 4.5% above the low.

DBVT is down 52.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.4%. DBV Technologies S.A. has posted a net loss over the last twelve months (EPS of -$3.00), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About DBV Technologies S.A.

Company profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Daniel Tassé
Headquarters
Châtillon
Employees
179
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, DBV Technologies S.A. generated $5.6 million in revenue, up 35.8% from fiscal 2024. DBV Technologies S.A. reported a net loss of $146.9 million, compared with a loss of $113.9 million a year earlier. Operating margin was -2609.2%.

DBV Technologies S.A. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$5.64M$4.15M$15.73M$4.84M$5.71M
Growth+35.77%-73.61%+224.69%-15.14%-49.38%
Net income$-146.95M$-113.92M$72.71M$96.27M$-97.81M
EPS (diluted)$-1.05$-1.17$-0.76$-1.24$-1.78

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$36.54+305.10%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $5.24High $47.18

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.70 vs $-0.60
Surprise
-16.67%

DBVT news

All DBVT news

DBV Technologies S.A. peers

Health Care sector
DBVT peer companies
CompanyPrice% ChgMarket capCompare
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs DBVT
FDMT4D Molecular Therapeutics Inc.10.23-4.57%$576.76Mvs DBVT
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs DBVT
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs DBVT
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs DBVT
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs DBVT
VALNValneva SE ADR5.16-3.82%$490.86Mvs DBVT
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs DBVT

Indexes, lists and sector

DBV Technologies S.A. stock FAQ

What is DBV Technologies S.A.'s stock price today?

DBVT last traded at $9.02 as of Nov 20, 4:00 PM EST, down 4.25% on the day. Prices are delayed at least 15 minutes.

Does DBV Technologies S.A. pay a dividend?

No. DBV Technologies S.A. does not currently pay a regular cash dividend.

Who is DBV Technologies S.A.'s CEO?

Mr. Daniel Tassé is the chief executive officer of DBV Technologies S.A. ADR, which has about 179 employees.

Has DBVT ever split its stock?

Yes. The most recent DBVT stock split was a 1-for-2 split on Jun 7, 2024.

What is the DBVT 52-week high?

The 52-week high for DBVT is $26.19 and the 52-week low is $8.63. The stock is currently 65.6% below its high.

Compare DBVT